



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

October 24, 2019

Jeffrey Nau  
Chief Executive Officer  
Oyster Point Pharma, Inc.  
202 Carnegie Center, Suite 109  
Princeton, NJ 08540

**Re: Oyster Point Pharma, Inc.  
Form S-1  
Exhibit No. 10.11  
Filed October 21, 2019  
File No. 333-234104**

Dear Dr. Nau:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance